Supplementary Table 2. Demographic and clinical characteristics of the COURAGE-PD cohort.

Principal Investigators	Country	Ancestry	Cases (N)	Controls (N)	Total (N)	Female cases (%)	Female controls (%)	Case age at enrolment (mean, SD in years)	Control age at enrolment (mean, SD in years)
Aasly	Norway	European	510	509	1019	40%	45.2%	77.7(11.6)	NA
Bardien/Carr	South Africa	European	170	85	255	38.8%	43.5%	68.7(10.6)	51.1(12.7)
Annesi	Italy	European	93	94	187	35.5%	54.3%	66.5(9.0)	58.2(20.3)
Brice	France	European	851	280	1131	41.6%	43.6%	60.7(10.9)	62.4(10.7)
Brighina	Italy	European	48	40	88	20.8%	40%	66.3(9.8)	66.7(5.3)
Carmine	Sweden	European	286	629	915	38.5%	44.8%	67.4(10.3)	NA
Chartier-Harlin	France	European	370	228	598	45.7%	60.1%	64.3(9.0)	59.9(12.6)
Deutschlander	Germany	European	285	46	331	38.2%	69.6%	69.4(9.9)	66.0(10.3)
Elbaz	France	European	455	1066	1521	40.2%	40.8%	70.1(7.4)	69.8(7.6)
Farrer	USA	European	389	409	798	34.4%	68.2%	67.7(10.3)	69.4(12.4)
Ferreira	Portugal	European	415	67	482	42.9%	74.6%	69.0(10.1)	47.1(17.8)
Gasser/Sharma	Germany	European	681	549	1230	36.4%	56.6%	64.9(10.9)	61.9(7.8)
Goldwurm	Italy	European	1391	1370	2761	40.8%	66.3%	65.8(10.8)	61.9(10.9)
Hadjigeorgiou	Greece	European	283	314	597	51.6%	52.9%	67.9(10.3)	69.8(8.7)
Koks	Estonia	European	216	170	386	60.2%	58.2%	73.0(8.2)	72.3(10.2)
Krainc	USA	European	59	16	75	25.4%	81.2%	64.7(10.7)	61.4(11.7)
Mellick	Australia	European	480	508	988	36.0%	54.7%	68.3(9.3)	66.9(9.6)
Pchelina	Russia	European	15	5	20	46.7%	80%	60.7(6.4)	59.8(20.0)
Puschmann	Sweden	European	110	105	215	37.3%	70.5%	68.8(10.6)	66.7(8.9)
Rogaeva	Canada	European	215	153	368	34.0%	62.1%	63.6(12.4)	73.8(8.6)
Stefanis	Greece	European	242	181	423	38.4%	64.1%	67.1(13.5)	67.0(9.6)
Valente	Italy	European	326	54	380	37.7%	61.1%	67.0(12.1)	78.4(9.6)
Wirdefeldt	Sweden	European	147	176	323	44.2%	54.5%	72.2(9.3)	73.5(9.7)
Zimprich	Austria	European	598	184	782	36.6%	59.2%	66.8(11.3)	NA
Kruger	Luxembourg	European	333	360	693	32.7%	44.2%	67.4(11.2)	58.1(11.9)
TOTAL	-	**European**	**8968**	**7598**	**16566**				

Supplementary Table 3. Demographic and clinical characteristics of the AMP-PD cohort.

Study	Cases (N)	Controls (N)	Total (N)	Female cases (%)	Female control (%)	Case age at onset (mean, SD in years)	Control age at last exam (mean, SD in years)
BIOFIND	75	56	131	38.7	48.2	67.5(6.2)	65.4(7.2)
HBS	524	392	916	36.3	64.0	61.5(10.6)	68.5(10.3)
LBD	-	1759	1759	-	49.5	-	71.9(13.5)
SURE-PD3	227	-	227	49.3	-	62.3(9.5)	-
PDBP	767	437	1204	35.6	55.1	59.6(10.6)	62.8(10.8)
PPMI	381	173	554	35.7	34.1	62.0(9.6)	61.0(10.4)
STEADY-PD3	274	-	274	30.7	-	62.7(9.2)	-
TOTAL	**2248**	**2817**	**5065**				

NA: Not Applicable

Supplementary Table 4. PD cases and controls in each quantile of polygenic risk scores per cohort.

Quantiles	IPDGC		COURAGE-PD		UKBB		AMP-PD	
	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases
1 (0 - 25%)	2353	926	1900	1520	3575	507	704	389
2 (26 - 50%)	2353	1396	1899	1961	3575	606	704	475
3 (51- 75%)	2353	1869	1899	2384	3575	678	704	585
4 (76- 100%)	**2353**	**3011**	**1900**	**3102**	**3576**	**847**	**705**	**798**
Total	9412	7204	7598	8968	14301	2639	2817	2248

Supplementary Table 5. Meta-GWAS summary statistics for the sub-top loci associated with PD resilience.

SNP	CHR	BP	Nearest Gene	Variant type	Effect allele	Other allele	Frequency	Beta (SE)	*P* value	I^2	Beta(SE) in Risk GWAS	P value in Risk GWAS
rs62325099	4	190552831	*LINC01262*	Intergenic	T	C	0.569	-0.328(0.061)	1.03e-07	NA	0.089(0.069)	0.206
rs2652202	5	77095148	*TBCA*	Intergenic	T	C	0.645	0.127(0.024)	1.64e-07	0	-0.023(0.022)	0.303
rs12245509	10	91752990	*LINC01375*	Intergenic	A	G	0.940	-0.248(0.049)	5.21e-07	0	0.016(0.045)	0.721
rs292289	18	5198809	*C18orf42*	Intergenic	C	A	0.144	-0.301(0.056)	9.85e-08	NA	-0.020(0.043)	0.641

SNP: single nucleotide polymorphism, CHR: chromosome, BP: base pair, SE: standard error. NA: not applicable. rs62325099 and rs292289 were only present in the discovery dataset (IPDGC). Risk GWAS means the Mike Nalls *et al.* 2019 PD GWAS.

Supplementary Table 6. Pearson correlation between risk and resilience scores in four groups of genetic cohorts.

Cohort	Group	Pearson's r	95%CI	P
IPDGC	Control	0.132	0.111, 0.151	**2.20E-16**
IPDGC	PD	-0.092	-0.115, -0.069	**2.20E-16**
IPDGC	Resilient-control	-0.027	-0.100, 0.0457	0.464
IPDGC	Risk-matching-PD	-0.001	-0.067, 0.065	0.970
COURAGE-PD	Control	0.022	-0.001, 0.044	0.058
COURAGE-PD	PD	-0.013	-0.033, -0.008	0.226
COURAGE-PD	Resilient-control	0.005	-0.040, 0.050	0.823
COURAGE-PD	risk-matching-PD	-0.021	-0.057, -0.014	0.233
AMP-PD	Control	0.0004	-0.036, 0.037	0.982
AMP-PD	PD	-0.004	-0.045, 0.037	0.843
AMP-PD	Resilient-control	-0.028	-0.102, 0.045	0.451
AMP-PD	Risk-matching-PD	-0.018	-0.087, 0.052	0.615
UKBB	Control	0.006	-0.010, 0.022	0.471
UKBB	PD	-0.012	-0.051, 0.026	0.523
UKBB	Resilient-control	0.009	-0.023, 0.042	0.571
UKBB	Risk-matching-PD	-0.011	-0.078, 0.056	0.745

Significant values are highlighted in bold.

Supplementary Table 7. Top ten ranked pathways associated with PD resilience.

Gene Set	N Genes	Beta	Beta STD	SE	P value	Pbon
GO_bp:go_histone_h3_k9_dimethylation	5	1.370	0.024	0.292	1.36e-06	**0.021**
Curated_gene_sets:burton_adipogenesis_7	40	0.582	0.028	0.137	1.16e-05	0.18
GO_mf:go_selenium_binding	7	1.446	0.026	0.326	5.25e-05	0.81
GO_cc:go_vcb_complex	6	1.500	0.028	0.390	5.98e-05	0.92
Curated_gene_sets:davicioni_pax_foxo1_signature_in_arms_up	48	0.473	0.025	0.130	0.000128	1
GO_bp:go_protein_localization_to_membrane	515	0.128	0.022	0.036	0.000169	1
GO_mf:go_calcium_channel_regulator_activity	45	0.444	0.023	0.126	0.000214	1
GO_bp:go_positive_regulation_of_voltage_gated_calcium_channel_activity	12	0.812	0.022	0.233	0.000242	1
GO_cc:go_microbody_membrane	53	0.336	0.019	0.097	0.000260	1
Curated_gene_sets:torchia_targets_of_ewsr1_fli1_fusion_dn	268	0.183	0.023	0.053	0.000290	1

MAGMA gene-set analysis is performed for curated gene sets and gene ontology (GO) terms obtained from MsigDB. GO_bp: GO biological process, GO_mf: GO molecular function, GO_cc: GO cellular component, N Genes: the number of genes in the data that was in the set, BETA: the regression coefficient of the variable, BETA STD: the semi-standardized regression coefficient, corresponding to the predicted change in Z-value given a change of one standard deviation in the predictor gene set/gene covariate (i.e., BETA divided by the variable's standard deviation), SE: the standard error of the regression coefficient, P_{bon}: Bonferroni adjusted p-value.

Supplementary Figure 1. Density plots displaying genetic risk profiling for PD cases and controls.

A. IPDGC



B. COURAGE-PD



C. UKBB



D. AMP-PD



Supplementary Figure 2. Quantile-quantile (QQ) plot showing the distribution of p-values from the genome-wide association study meta-analysis of resilience to PD (grey dots) compared to a theoretical distribution of p-values for an equivalent number of variants (red dashed line).



Supplementary Figure 3. Power calculations at meta-GWAS sample size.

A. Top-25% of the data



B. Top-10% of the data



Supplementary Figure 4. Gene-based MAGMA analysis.

A



B



C



A) Gene-based Manhattan plot. B) Locus zoom plot of the TBCA region nominated through MAGMA gene-based analyses. Each SNP is color-coded based on the highest r2 to one of the independent significant SNPs if that is greater or equal to the user-defined threshold. Other SNPs (i.e. below the user-defined r^2) are colored in grey. The top lead SNPs in genomic risk loci, lead SNPs, and independent significant SNPs are circled in black and colored in dark-purple, purple and red, respectively. C) Quantile-quantile (QQ) plot showing the distribution of p-values from MAGMA gene-based GWAS of resilience to PD (grey dots) compared to a theoretical distribution of p-values for an equivalent number of variants (red dashed line).

Supplementary Figure 5. Polygenic resilience score of resilient controls and risk-matching cases.

A. IPDGC



B. COURAGE-PD



C. UKBB



D. AMP-PD



Supplementary Figure 6. Correlation between risk and resilience scores in the discovery IPDGC cohort, including 7,204 PD cases and 9,412 controls.



Supplementary Figure 7. Tissue specific expression enrichment analyses for PD resilience variants.



Supplementary Figure 8. Cell type expression enrichment analyses for PD resilience variants.



COURAGE-PD consortium members and affiliations:

First Name	Last Name	Institute	Country	E-mail address
Sulev	Koks	Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia, Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia	Australia	sulev.koks@murdoch.edu.au
George D	Mellick	Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia	Australia	georgedmellick@gmail.com
Walter	Pirker	Department of Neurology, Wilhelminenspital, Austria	Austria	walter.pirker@gesundheitsverbund.at
Alexander	Zimprich	Department of Neurology, Medical University of Vienna, Austria	Austria	alexander.zimprich@meduniwien.ac.at
Anthony E	Lang	Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada; Division of Neurology, University of Toronto, Toronto, Ontario, Canada; Krembil Brain Institute, Toronto, Ontario, Canada	Canada	Anthony.Lang@uhnresearch.ca
Ekaterina	Rogaeva	Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada	Canada	ekaterina.rogaeva@utoronto.ca
Pille	Taba	Department of Neurology and Neurosurgery, University of Tartu, Estonia; Neurology Clinic, Tartu University Hospital, Tartu, Estonia	Estonia	Pille.Taba@kliinikum.ee
Alexis	Brice	Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France	France	alexis.brice@upmc.fr
Marie-Christine	Chartier-Harlin	Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Lille Neurosciences & Cognition, F-59000 Lille, France	France	marie-christine.chartier-harlin@inserm.fr
Jean-Christophe	Corvol	Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France Assistance Publique Hôpitaux de Paris, Department of Neurology, CIC Neurosciences, Paris, France	France	jean-christophe.corvol@aphp.fr
Cloé	Domenighetti	Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team " Exposome, heredity, cancer and health ", CESP, 94807, Villejuif, France.	France	cloe.domenighetti@inserm.fr
Alexis	Elbaz	Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team " Exposome, heredity, cancer and health ", CESP, 94807, Villejuif, France.	France	alexis.elbaz@inserm.fr

Suzanne	Lesage	Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurologie, Paris, France	France	suzanne.lesage@upmc.fr
Eugenie	Mutez	Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Lille Neurosciences & Cognition, F-59000 Lille, France	France	eugenie.mutez@chru-lille.fr
Pierre-Emmanuel	Sugier	Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team " Exposome, heredity, cancer and health ", CESP, 94807, Villejuif, France.	France	pierre-emmanuel.sugier@inserm.fr
Ashwin	Ashok Kumar Sreelatha	Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry , University of Tubingen, Germany	Germany	ashwin.ashok-kumar-sreelatha@uni-tuebingen.de
Sandeep	Grover	Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry , University of Tubingen, Germany	Germany	sandeep.grover@uni-tuebingen.de
Kathrin	Brockmann	Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany	Germany	kathrin.brockmann@uni-tuebingen.de
Angela B	Deutschländer	Department of Neurology, Ludwig Maximilians University of Munich, Germany Department of Neurology, Max Planck Institute of Psychiatry, Munich, Germany Department of Neurology and Department of Clinical Genomics, Mayo Clinic Florida, Jacksonville, FL, USA	Germany	adeutschlaender@gmx.com
Thomas	Gasser	Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany	Germany	thomas.gasser@uni-tuebingen.de
Jens	Krüger	Group of Applied Bioinformatics, University of Tubingen, Germany	Germany	jens.krueger@uni-tuebingen.de.
Peter	Lichtner	Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.	Germany	lichtner@helmholtz-muenchen.de
Milena	Radivojkov-Blagojevic	Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.	Germany	milena.radivojkov@helmholtz-muenchen.de
Claudia	Schulte	Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany. German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany.	Germany	claudia.schulte@uni-tuebingen.de
Manu	Sharma	Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Germany	Germany	manu.sharma@uni-tuebingen.de

Efthimos	Dardiotis	Laboratory of Neurogenetics, Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Greece	Greece	edar@med.uth.gr
Georges M	Hadjigeorgiou	Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece	Greece	hadjigeorgiou.georgios@ucy.ac.cy
Athina Maria	Simitsi	1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece	Greece	simitsh@yahoo.gr
Leonidas	Stefanis	Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece	Greece	lstefanis@bioacademy.gr
Grazia	Annesi	Institute for Biomedical Research and Innovation, National Research Council, Cosenza, Italy	Italy	grazia.annesi@cnr.it
Laura	Brighina	Department of Neurology, San Gerardo Hospital, Monza, Italy Department of Medicine and Surgery and Milan Center for Neuroscience, University of Milano Bicocca, Milano, Italy	Italy	brighinalaura@hotmail.com
Carlo	Ferrarese	Department of Neurology, San Gerardo Hospital, Monza, Italy Department of Medicine and Surgery and Milan Center for Neuroscience, University of Milano Bicocca, Milano, Italy	Italy	carlo.ferrarese@unimib.it
Simona	Petrucci	Department of Clinical and Molecular Medicine, University of Rome, Italy UOC Medical Genetics and Advanced Cell Diagnostics, S. Andrea University Hospital, Rome, Italy.	Italy	simona.petrucci@uniroma1.it
Gianni	Pezzoli	Parkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italy	Italy	pezzoli@parkinson.it
Andrea	Quattrone	Institute of Neurology, Magna Graecia University, Catanzaro, Italy	Italy	an.quattrone@hotmail.it
Letizia	Straniero	Department of Biomedical Sciences, Humanitas University, Milan, Italy	Italy	Letizia.Straniero@humanitasresearch.it
Monica	Gagliardi	Institute of Molecular Bioimaging and Physiology National Research Council, Catanzaro, Italy	Italy	monicg_2002@yahoo.it
Enza Maria	Valente	Department of Molecular Medicine, University of Pavia, Italy Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy	Italy	enzamaria.valente@unipv.it
Anna	Zecchinelli	Parkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italy	Italy	Anna.Zecchinelli@asst-pini-cto.it
Nobutaka	Hattori	Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan	Japan	nhattori@juntendo.ac.jp

Akiyoshi	Nakayama	Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama 359-8513, Japan.	Japan	aknak@ndmc.ac.jp
Hirotaka	Matsuo	Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama 359-8513, Japan	Japan	matsuo29@gmail.com
Kenya	Nishioka	Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan	Japan	nishioka@juntendo.ac.jp
Dheeraj	Bobbili	Bioinformatics Core, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.	Luxembourg	dheeraj.bobbili@uni.lu
Rejko	Kruger	Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg Parkinson's Research Clinic, Centre Hospitalier de Luxembourg, Luxembourg Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg	Luxembourg	rejko.krueger@uni.lu
Zied	Landoulsi	Bioinformatics Core, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg	Luxembourg	zied.landoulsi@uni.lu
Patrick	May	Bioinformatics Core, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.	Luxembourg	patrick.may@uni.lu
Lukas	Pavelka	Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg	Luxembourg	lukas.pavelka@uni.lu
Bastiaan R	Bloem	Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands.	Netherland	bas.bloem@radboudumc.nl
Bart PC van de	Warrenburg	Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands.	Netherland	Bart.vandeWarrenburg@radboudumc.nl
Jan	Aasly	Department of Neurology, St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway	Norway	jan.aasly@ntnu.no
Lasse	Pihlstrøm	Department of Neurology, Oslo University Hospital, Oslo, Norway	Norway	lasse.pihlstrom@medisin.uio.no
Mathias	Toft	Department of Neurology, Oslo University Hospital, Oslo, Norway	Norway	mathias.toft@gmail.com
Joaquim J	Ferreira	Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal	Portugal	joaquimjferreira@gmail.com
Leonor	Correia Guedes	Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. Campus Neurológico Sénior, Torres Vedras, Portugal.	Portugal	lcorreiaguedes@gmail.com

		Department of Neurosciences and Mental Health, Neurology, Hospital de Santa Maria, CHULN, Lisbon, Portugal.		
Soraya	Bardien	Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; South African Medical Research Council/ Stellenbosch University Genomics of Brain Disorders Research Unit, Cape Town, South Africa	South Africa	sbardien@sun.ac.za
Jonathan	Carr	Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; South African Medical Research Council/ Stellenbosch University Genomics of Brain Disorders Research Unit, Cape Town, South Africa	South Africa	jcarr@sun.ac.za
Sun Ju	Chung	Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea	South Korea	sunjubrain@gmail.com
Yun Joong	Kim	Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea	South Korea	yunjkim@yuhs.ac
Monica	Diez-Fairen	Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain; Movement Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain	Spain	monicadifa@gmail.com
Mario	Ezquerra	Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, ES-08036 Barcelona, Catalonia, Spain	Spain	ezquerra@clinic.cat
Pau	Pastor	Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain; Movement Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain	Spain	pastorpau@gmail.com
Eduardo	Tolosa	Parkinson's disease & Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona, Spain	Spain	etolosa@clinic.cat
Andrea C	Belin	Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden	Sweden	Andrea.Carmine.Belin@ki.se
Nancy L	Pedersen	Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden	Sweden	nancy.pedersen@ki.se
Andreas	Puschmann	Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Getingevägen 4, 221 85, Lund, Sweden.	Sweden	andreas.puschmann@med.lu.se

Caroline	Ran	Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden	Sweden	Caroline.Ran@ki.se
Emil Y	Rödström	Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Getingevägen 4, 221 85, Lund, Sweden	Sweden	emil.ygland_rodstrom@med.lu.se
Karin	Wirdefeldt	Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden	Sweden	Karin.Wirdefeldt@ki.se
Carl E	Clarke	University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust, United Kingdom	UK	carlclarke@nhs.net
Karen E	Morrison	Faculty of Medicine, Health and Life Sciences, Queens University, Belfast, United Kingdom	UK	k.morrison@qub.ac.uk
Manuela	Tan	Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK	UK	manuela.tan@ucl.ac.uk
Connor	Edsall	Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD 20892, USA	US	Cwedsall@vt.edu
Matt J	Farrer	Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL, USA	US	m.farrer@ufl.edu
Dimitri	Krainc	Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States	US	krainc@northwestern.edu
Andrew B	Singleton	Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD 20892, USA Center For Alzheimer's and Related Dementias, NIA, NIH, Bethesda, MD 20892, USA	US	singleta@mail.nih.gov
Lena F	Burbulla	Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA German Center for Neurodegenerative Diseases (DZNE), Munich, Germany Metabolic Biochemistry, Biomedical Center 13 (BMC), Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany	US	lena.burbulla@northwestern.edu
Dena G	Hernandez	Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD 20892, USA	US	dh326e@nih.gov

AMP-PD acknowledgement:

We would like to thank all members of the Comprehensive Unbiased Risk factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) Consortium. The COURAGE-PD consortium is conducted under a partnership agreement between 35 studies. The COURAGE-PD consortium is supported by the EU Joint Program for Neurodegenerative Disease research (JPND; https://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/closed-calls/risk-factors-2012/risk-factor-call-results/courage-pd/, grant 01ED1406).

We would like to thank AMP-PD for the publicly available whole-genome sequencing data. Clinical data and biosamples used in preparation of this article were obtained from the Michael J. Fox Foundation (MJFF) and National Institutes of Neurological Disorders and Stroke (NINDS) BioFIND study, Harvard Biomarkers Study (HBS), the NIA International Lewy Body Dementia Genetics Consortium Genome Sequencing in Lewy body dementia case-control cohort (LBD), the MJFF LRRK2 Cohort Consortium (LCC), the NINDS Parkinson's disease Biomarkers Program (PDBP), MJFF Parkinson's Progression Marker Initiative (PPMI), and the NINDS Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease, Phase 3 (STEADY-PD3). BioFIND is sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF) with support from the National Institute for Neurological Disorders and Stroke (NINDS). The BioFIND Investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit michaeljfox.org/news/biofind. Genome sequence data for the Lewy body dementia case-control cohort were generated at the Intramural Research Program of the U.S. National Institutes of Health. The study was supported in part by the National Institute on Aging (program #: 1ZIAAG000935) and the National Institute of Neurological Disorders and Stroke (program #: 1ZIANS003154). The Harvard NeuroDiscovery Biomarker Study (HBS) is a collaboration of HBS investigators [full list of HBS investigator found at https://www.bwhparkinsoncenter.org/biobank/ and funded through philanthropy and NIH and Non-NIH funding sources. The HBS Investigators have not participated in reviewing the data analysis or content of the manuscript. The LRRK2 Cohort Consortium is coordinated and funded by The Michael J. Fox Foundation for Parkinson's Research. Data used in preparation of this article were obtained from the MJFF-sponsored LRRK2 Cohort Consortium (LCC). The LCC Investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit https://www.michaeljfox.org/biospecimens. PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including [list the full names of all of the PPMI funding partners found at www.ppmi-info.org/fundingpartners. The PPMI Investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit www.ppmi-info.org. Parkinson's Disease Biomarker Program (PDBP) consortium is supported by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health. A full list of PDBP investigators can be

found at https://pdbp.ninds.nih.gov/policy. The PDBP Investigators have not participated in reviewing the data analysis or content of the manuscript. The Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease, Phase 3 (STEADY-PD3) is funded by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health with support from the Michael J. Fox Foundation and the Parkinson Study Group. For additional study information, visit https://clinicaltrials.gov/ct2/show/study/NCT02168842. The STEADY-PD3 investigators have not participated in reviewing the data analysis or content of the manuscript. The Study of Urate Elevation in Parkinson's Disease, Phase 3 (SURE-PD3) is funded by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health with support from the Michael J. Fox Foundation and the Parkinson Study Group. For additional study information, visit https://clinicaltrials.gov/ct2/show/NCT02642393. The SURE-PD3 investigators have not participated in reviewing the data analysis or content of the manuscript. The LRRK2 Cohort Consortium (LCC) was created to assemble and study groups of people with and without Parkinson's disease who carry mutations in the LRRK2 gene. The LRRK2 Cohort Consortium is coordinated and funded by The Michael J. Fox Foundation for Parkinson's Research. The investigators within the LCC contributed to the design and implementation of the LCC and/or provided data and/or collected biospecimens, but did not necessarily participate in the analysis or writing of this report. The full list of LCC investigators can be found at www.michaeljfox.org/lccinvestigators. This work utilized the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov).